An antibody against L1CAM protein
By developing anti-L1CAM protein antibodies with specific amino acid sequences, the problems of insufficient antibody affinity and specificity in existing technologies have been solved, enabling efficient recognition and binding of L1CAM protein and neuronal exosomes, and expanding its application in disease diagnosis and treatment.
Patent Information
- Application Number
- CN202411216949.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-02
AI Technical Summary
The lack of high-affinity and specific anti-L1CAM protein antibodies in existing technologies limits their application in disease detection and treatment.
An anti-L1CAM protein antibody containing a specific amino acid sequence, including complementary determinant regions of the heavy and light chain variable regions, was developed to target and efficiently bind to the L1CAM protein.
It achieves highly specific recognition and binding of L1CAM protein and neuronal exosomes, expanding its application potential in disease diagnosis and treatment.
Smart Images

Figure CN118725119B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of cell biotechnology and immunology, and relates to an antibody against L1CAM protein. Specifically, the present invention relates to an antibody 8D12 for detecting L1CAM protein or neuronal exosomes and related detection products and uses thereof. Background Art
[0002] In recent years, with the continuous development of biomedicine, the application of antibodies has become more and more extensive. They have not only been used in clinical and biological experimental detection work, but also in the treatment and diagnosis of diseases. Several derivatives based on monoclonal antibodies: bispecific antibodies, antibody-drug conjugates are also developing rapidly. In terms of detection, in the commonly used immunoassay techniques based on the antigen-antibody binding mechanism (immunoblotting, enzyme-linked immunosorbent assay, immunofluorescence, immunohistochemistry, immunoprecipitation, etc.), the appropriateness of antibody selection directly affects the results. In terms of treatment, compared with polyclonal antibodies, monoclonal antibodies show stronger specificity and higher purity. Based on the high specificity of monoclonal antibodies and the progress of monoclonal antibody humanization technology, more and more monoclonal antibodies have played an important role in the targeted treatment and diagnosis of diseases.
[0003] L1CAM (L1 cell adhesion molecule) is an important neural cell adhesion molecule, a member of the immunoglobulin superfamily. The protein it encodes contains an intracellular domain, a single transmembrane region, and an extracellular domain containing 6 immunoglobulin (Ig) and 5 fibronectin (Fn) class III motifs. It is mainly expressed in the nervous system and plays a key role in cell adhesion dynamics and transmembrane signaling during the development of the nervous system, affecting processes such as neuronal migration, axon growth, fasciculation, and synaptogenesis. L1CAM antibodies are an important research tool that can effectively isolate and detect neural-derived exosomes to study their role in neuronal communication, the occurrence and development of neuro-related diseases, etc. In addition, L1CAM is also of great significance in tumorigenesis and as a target for anticancer therapy. Related studies have shown that L1CAM antibody treatment can inhibit tumor spread.
[0004] Therefore, the development of a new generation of anti-L1CAM protein antibodies has important scientific and application value, and screening for L1CAM proteins with strong affinity will expand their application in the occurrence and development of diseases. Summary of the invention
[0005] The first objective of the present application is to provide an antibody targeting L1CAM protein, and related derivative products thereof.
[0006] The second objective of the present application is to provide the use of the above-mentioned antibody in detecting L1CAM protein or neuronal exosomes.
[0007] In order to achieve the above objectives, this application specifically adopts the following technical solutions:
[0008] In a first aspect, the present application provides an antibody against L1CAM protein.
[0009] Furthermore, the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises heavy chain complementary determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises light chain complementary determining regions LCDR1, LCDR2 and LCDR3.
[0010] Furthermore, the amino acid sequences of the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 3, 4 and 5, respectively, and the amino acid sequences of the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 10, 11 and 12, respectively.
[0011] "Antibody" refers to any form of an antibody that exhibits a desired biological activity (e.g., inhibiting the binding of a ligand to its receptor or by inhibiting ligand-induced receptor signal transduction). Therefore, "antibody" is used in its broadest sense and explicitly includes, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies and multispecific antibodies (e.g., bispecific antibodies), fully human, humanized, primatized, chimeric antibodies, single-chain antibodies, etc.
[0012] "Complementarity determining region" or "CDR region" or "CDR" or "hypervariable region" is a region of an antibody variable domain that is highly variable in sequence and forms structurally defined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigen epitopes.
[0013] Based on the variable region amino acid sequence contained in a given antibody or fragment thereof of the present invention, those skilled in the art can routinely determine the CDR contained therein. For example, the CDR in the variable region amino acid sequence is defined using the Kabat scheme, the AbM scheme, the Chothia scheme or the Contact scheme.
[0014] When referring to antibodies defined by specific CDR sequences defined herein, the scope of the antibodies also covers antibodies whose variable region sequences comprise the specific CDR sequences but whose declared CDR boundaries differ from the specific CDR boundaries defined herein due to the application of a different scheme (e.g., a different assignment system rule or combination).
[0015] The CDR of the antibody of the present invention can be manually assessed to determine the boundaries according to any scheme or combination thereof in the art. Unless otherwise specified, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined in any of the above ways.
[0016] Furthermore, the antibody has any one of the amino acid sequences shown in (I)-(III):
[0017] (I) the heavy chain variable region sequence shown in SEQ ID NO: 1 and the light chain variable region sequence shown in SEQ ID NO: 2;
[0018] (II) an amino acid sequence that has at least 90% homology to the amino acid sequence shown in SEQ ID NO: 1-2 and has the same function;
[0019] (III) An amino acid sequence obtained by modifying, replacing, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO: 1-2 and having the same function.
[0020] In some embodiments, functional variants of the antibodies described in the present invention are also included in the scope of protection of the present invention, and the "functional variant" refers to a protein having a significant or significant sequence identity or similarity compared to a parent antibody, and the functional variant retains the biological activity of the parent antibody. Functional variants encompass, for example, the following variants of the antibodies (parent antibodies) described herein, which retain the ability to recognize target cells to a similar extent, to the same extent, or to a higher extent than the parent antibody. With reference to the parent antibody, the functional variant may, for example, have at least about 30%, 50%, 70%, 75%, 80%, 85%, 90%, 95% or more homology with the parent antibody in terms of amino acid sequence.
[0021] Further, the functional variant may, for example, comprise the amino acid sequence of a parent antibody having at least one conservative amino acid substitution. As an alternative or supplement, the functional variant may comprise the amino acid sequence of a parent antibody having at least one non-conservative amino acid substitution. In this case, the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant. The non-conservative amino acid substitution may enhance the biological activity of the functional variant, so that the biological activity of the functional variant is improved compared to the parent antibody.
[0022] Further, conservative amino acid substitutions are known in the art and include substitutions in which one amino acid having particular physical and / or chemical properties is exchanged for another amino acid having the same or similar chemical or physical properties. For example, conservative amino acid substitutions can be substitutions of an acidic / negatively charged polar amino acid for another acidic / negatively charged polar amino acid (e.g., Asp or Glu), substitutions of an amino acid with a non-polar side chain for another amino acid with a non-polar side chain (e.g., Ala, Gly, Val, He, Leu, Met, Phe, Pro, Trp, Cys, Val, etc.), substitutions of a basic / positively charged polar amino acid for another basic / positively charged polar amino acid (e.g., Lys, His, Arg, etc.), substitutions of an uncharged amino acid with a polar side chain for another uncharged amino acid with a polar side chain (e.g., Asn, Gin, Ser, Thr, Tyr, etc.), substitutions of an amino acid with a β-branched side chain for another amino acid with a β-branched side chain (e.g., He, Thr and Val), substitutions of an amino acid with an aromatic side chain for another amino acid with an aromatic side chain (e.g., His, Phe, Trp and Tyr).
[0023] Those skilled in the art can easily mutate the nucleotide sequence corresponding to the antibody of the present invention by using known methods, such as directed evolution and point mutation. Those artificially modified nucleotides having 90% or more homology with the nucleotide sequence corresponding to the antibody of the present invention or its antigen-binding fragment, as long as they encode the above-mentioned antibody of the present invention, are derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention, and are also included in the protection scope of the present invention.
[0024] In a second aspect, the present application provides a biomaterial.
[0025] Further, the biomaterial comprises:
[0026] 1) A polynucleotide encoding the antibody according to the first aspect of the present invention;
[0027] 2) a vector comprising the polynucleotide described in 1);
[0028] 3) A host cell comprising the polynucleotide described in 1) or the vector described in 2).
[0029] Furthermore, the polynucleotide sequence encoding the heavy chain variable region of the antibody described in the first aspect of the present invention is shown as SEQID NO: 17; the polynucleotide sequence encoding the light chain variable region of the antibody described in the first aspect of the present invention is shown as SEQID NO: 18.
[0030] Furthermore, the vector includes linear polynucleotides, plasmids, and viral vectors.
[0031] Furthermore, the host cells include prokaryotic cells and eukaryotic cells.
[0032] In the present invention, the polynucleotide may comprise natural, non-natural or altered nucleotides; and it may comprise natural, non-natural or altered internucleotide connections, such as phosphoramidate connections or phosphorothioate connections, replacing the phosphodiester present between the nucleotides of the unmodified oligonucleotide. In some embodiments, the nucleic acid does not comprise any insertion, deletion, inversion and / or replacement. However, in some cases for nucleic acid, it may be suitable to comprise one or more insertions, deletions, inversions and / or replacements, and therefore, the nucleic acids formed by these insertions, deletions, inversions and / or replacements are also within the scope of the present invention.
[0033] When applied to polynucleotides, the term "encoding" refers to a polynucleotide that is "encoding" a polypeptide if it can be transcribed and / or translated to produce mRNA for a polypeptide and / or its fragments in its native state or when manipulated by methods well known to those skilled in the art. The antisense strand is the complement of such a nucleic acid, and the coding sequence can be deduced therefrom.
[0034] In some embodiments, the methods of introducing the above-mentioned vector into the host cell include physical methods, chemical methods, and biological methods; preferably, the physical method includes calcium phosphate precipitation, lipid transfection, particle bombardment, microinjection, and electroporation; preferably, the chemical method includes a colloidal dispersion system and a lipid-based system; preferably, the biological method includes a DNA vector, a lentiviral vector, a poxvirus vector, a herpes simplex virus vector, an adenovirus vector, and an adeno-associated virus vector.
[0035] In some embodiments, examples of vectors that can be used in the present invention include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes, and vectors of viral origin. Various vectors known in the art can be selected, for example, commercially available vectors are selected, and then the nucleotide sequence encoding the above-mentioned antibody or antigen-binding fragment thereof is operably linked to the expression regulatory sequence to form an expression vector. In some embodiments, the vectors of viral origin include, but are not limited to, lentiviral vectors, retroviral vectors, adenoviral vectors, adeno-associated viral vectors, poxvirus vectors, herpesvirus vectors, baculovirus vectors, papillomavirus vectors, and papillomas.
[0036] In some embodiments, the expression vector may contain expression regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host cell (e.g., bacteria, fungi, plants, or animals) into which the vector is to be introduced, depending on the circumstances and whether the vector is DNA-based or RNA-based. The recombinant expression vector may contain restriction sites to facilitate cloning.
[0037] In some embodiments, the vector may also contain one or more marker genes that allow selection of transformed or transfected host cells. Marker genes include biocide resistance (e.g., resistance to antibiotics, heavy metals, etc.); complementation of prototrophy in auxotrophic hosts, etc. Suitable marker genes for expression vectors of the present invention include, for example, neomycin / G418 resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, ampicillin resistance genes, kanamycin resistance genes, puromycin resistance genes, etc.
[0038] In some embodiments, the host cell includes eukaryotic cells and prokaryotic cells. In some embodiments, the eukaryotic cells include, but are not limited to, mammalian cells, insect cells, plant cells, and yeast cells. The prokaryotic cells include, but are not limited to, bacteria, actinomycetes, cyanobacteria, mycoplasmas, chlamydia, and rickettsia. In some embodiments, the host cells used to express the antibodies of the present invention include Escherichia coli, yeast cells, insect cells, COS cells, CHO cells, and the like. Preferably, the host cell is a eukaryotic cell, and more preferably a mammalian cell.
[0039] In a third aspect, the present application provides any one of the following methods.
[0040] Further, the method comprises:
[0041] (1) A method for preparing the antibody of the first aspect of the present invention, the method comprising the following steps: culturing the host cell of the second aspect of the present invention to obtain a culture product, and isolating and purifying the antibody of the first aspect of the present invention from the culture product;
[0042] (2) A method for detecting L1CAM protein or neuronal exosomes in a sample for a non-diagnostic purpose, the method comprising the following steps: contacting the antibody described in the first aspect of the present invention with a sample to be tested, and detecting the formation of an immune complex between L1CAM protein or neuronal exosomes and the antibody;
[0043] (3) A method for enriching CNS-derived exosomes, the method comprising the step of contacting the antibody described in the first aspect of the present invention with a biological fluid of a subject.
[0044] Furthermore, the biological fluid includes blood, plasma, serum or saliva.
[0045] In a fourth aspect, the present application provides an antibody derivative.
[0046] Furthermore, the antibody derivative is a complex obtained by modifying the antibody described in the first aspect of the present invention.
[0047] Furthermore, the modification includes the use of detectable marker conjugation modification, therapeutic agent conjugation modification, and imaging agent conjugation modification.
[0048] Furthermore, the detectable markers include fluorescent pigments, avidin, radioactive isotopes, enzyme markers, dyes, and biotin.
[0049] Furthermore, the therapeutic agent includes radioisotopes, toxin moieties, toxoid hormone preparations, proteasome inhibitors, chemotherapeutic agents, cytokines.
[0050] In some embodiments, an antibody of the invention is one that has been modified with a functional moiety by labeling with a detectable marker, such as a radioisotope, enzyme, dye or biotin, or other affinity agent.
[0051] Furthermore, the detectable markers include fluorescent pigments, avidin, radioactive isotopes, enzyme markers, dyes, and biotin.
[0052] Furthermore, the therapeutic agent includes a radioisotope or radionuclide, a toxin moiety, a toxoid hormone preparation, a proteasome inhibitor, a chemotherapeutic agent, or a cytokine.
[0053] In some embodiments of the invention, the antibodies of the invention are antibodies that have been functionally partially modified (conjugated to a therapeutic agent), such as a radioisotope or radionuclide (e.g. 111 In or 90 Y), a toxin moiety (e.g., tetanus toxoid or ricin), a toxoid, or a chemotherapeutic agent.
[0054] In some embodiments, the antibodies of the invention are antibodies modified by conjugation of an imaging agent. The imaging agent may include, for example, a labeling moiety (e.g., biotin, a fluorescent moiety, a radioactive moiety, a histidine or myc tag or other peptide tag) for easy separation or detection.
[0055] In some embodiments, the antibodies, polynucleotides, vectors, and host cells provided by the present invention can also be included in pharmaceutical compositions, more particularly in pharmaceutical preparations, so as to be used for various purposes according to actual needs. The pharmaceutical composition also contains a second therapeutic agent and / or optionally a pharmaceutical excipient, and the second therapeutic agent is selected from cytokines, antibodies, chemotherapeutic agents, and small molecule drugs. The term "pharmaceutical composition" refers to a composition that exists in a form that allows the biological activity of the active ingredients contained therein to be effective, and does not contain additional ingredients that are unacceptably toxic to the subject to whom the composition is administered. The pharmaceutical composition includes, but is not limited to, carriers, diluents, adjuvants, excipients, preservatives, fillers, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, flavoring agents, antibacterial agents, antifungal agents, lubricants, dispersants, temperature-sensitive materials, temperature regulators, adhesives, stabilizers, suspending agents, etc.
[0056] In some embodiments, the pharmaceutical compositions described above can be administered by any suitable route known in the art, including but not limited to oral, nasal, intradermal, subcutaneous, intravenous, intramuscular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic and / or cerebrospinal.
[0057] In some embodiments, the above-mentioned composition can be formulated into a pharmaceutical composition suitable for intravenous injection into the human body according to conventional steps. Compositions for intravenous administration are generally solutions in sterile isotonic aqueous buffers. The pharmaceutical composition may also include a solubilizer and a local anesthetic such as lidocaine to relieve pain at the injection site. Generally speaking, the active ingredients are supplied alone or mixed together in a unit dose form, such as in the form of a dry lyophilized powder or anhydrous concentrate in a sealed container (such as an ampoule or a pouch) that indicates the amount of active agent. In the case of administering the composition by infusion, the composition can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. In the case of administering the composition by injection, an ampoule of sterile water or saline for injection can be used so that the active ingredient can be mixed before administration.
[0058] The antibodies of the present invention can be used in combination with at least one additional therapeutic agent to enhance the therapeutic effect; for example, in combination with immunotherapy drugs, targeted therapy drugs, chemotherapy drugs, etc.
[0059] In a fourth aspect, the present application provides a product.
[0060] Furthermore, the product includes the antibody described in the first aspect of the present invention, the biomaterial described in the second aspect of the present invention, and the antibody derivative described in the third aspect of the present invention.
[0061] Furthermore, the products include test kits, chromatography test strips, and chips.
[0062] Furthermore, the kit includes an ELISA detection kit, an immunofluorescence detection kit, a flow cytometry kit, and an IHC detection kit.
[0063] In some embodiments, the kit further comprises a container, instructions for use, a buffer, etc. In other embodiments, the kit further comprises a lysis medium for dissolving the sample to be tested, universal reagents and buffers required for detection, such as various buffers, detection labels, detection substrates, etc. The detection kit can be an in vitro diagnostic device.
[0064] In a fifth aspect, the present application provides an application.
[0065] Further, the application includes any of the following:
[0066] 1) Use of the antibody described in the first aspect of the present application, the biological material described in the second aspect of the present application, and the antibody derivative described in the third aspect of the present application in the preparation, detection, identification or screening of L1CAM protein products;
[0067] 2) Use of the antibody described in the first aspect of the present application, the biomaterial described in the second aspect of the present application, and the antibody derivative described in the third aspect of the present application in the preparation of a product for detecting or capturing neuronal exosomes;
[0068] 3) Use of the antibody described in the first aspect of the present application, the biomaterial described in the second aspect of the present application, and the antibody derivative described in the third aspect of the present application in the preparation of products for diagnosing neurodegenerative diseases.
[0069] Furthermore, the neurodegenerative diseases include but are not limited to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0070] In a sixth aspect, the present application provides a method for diagnosing tumors or neurodegenerative diseases.
[0071] Furthermore, the method comprises contacting the antibody described in the first aspect of the present invention with a sample to be tested, and detecting the formation of an antibody immune complex.
[0072] Furthermore, the tumors include melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, and endometrial cancer.
[0073] Furthermore, the neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0074] In a seventh aspect, the present application provides a method for treating a disease or condition in a subject in need thereof, comprising administering to the subject the antibody described in the first aspect of the present invention, the biomaterial described in the second aspect of the present invention, or the antibody derivative described in the third aspect of the present invention.
[0075] Furthermore, the disease or condition includes a tumor or a neurodegenerative disease.
[0076] Furthermore, the tumors include melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, and endometrial cancer.
[0077] Furthermore, the neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
[0078] In some embodiments, the antibodies of the present invention can be used to treat L1CAM protein-related diseases, for example, an effective amount of the antibodies of the first aspect of the present invention is administered to a subject in need, the subject being a subject suffering from a L1CAM-related disease, the administration method including parenteral, intrapulmonary and intranasal, and if local treatment is required, intralesional administration. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Administration can be by any appropriate route known to those skilled in the art, for example, by injection, such as intravenous or subcutaneous injection, which depends in part on whether the administration is short-term or long-term. A variety of dosing schedules are contemplated herein, including but not limited to: single or multiple administrations at multiple time points, push administration and pulse infusion. The L1CAM-related diseases include cancers, such as melanoma, neuroblastoma, ovarian cancer, colon cancer, pancreatic cancer, endometrial cancer, etc. BRIEF DESCRIPTION OF THE DRAWINGS
[0079] Figure 1 This is the electrophoresis diagram of L1CAM protein antibody 8D12 recognizing neuronal exosomes. DETAILED DESCRIPTION
[0080] The materials, methods and examples described herein are illustrative only and are not intended to be limiting. Other features, objects and advantages of the present invention will be apparent from this specification and the accompanying drawings and from the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those of ordinary skill in the art.
[0081] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.
[0082] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0083] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.
[0084] As used herein, the term "comprising" or "including" means including the described elements, integers or steps, but does not exclude any other elements, integers or steps. In this article, when the term "comprising" or "including" is used, unless otherwise specified, the situation consisting of the described elements, integers or steps is also covered.
[0085] As used herein, the term "binding" or "specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen binding site to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA) or conventional binding assays known in the art.
[0086] As used herein, the term "homology" is interchangeably used with the term "identity" and refers to sequence similarity to an amino acid sequence or nucleotide sequence to be compared. "Identity" includes amino acid sequences having 70% or more, or 75% or more, or 85% or more, or 90% or more, or 95% or more homology to the amino acid sequence provided by the present invention. Homology can be evaluated by the naked eye or by computer software. Using computer software, the identity between two or more sequences can be expressed as a percentage (%), which can be used to evaluate the homology between related sequences. The 70% or more homology can be 70%, 75%, 80%, 85%, 90% or more homology.
[0087] As used herein, the term "monoclonal antibody" refers to a preparation of an antibody molecule having a single amino acid composition, and does not refer to the method of its preparation. Monoclonal antibodies or immunologically active fragments thereof can be produced by hybridoma technology, recombinant technology, phage display technology, synthetic technology, etc. or other production techniques known in the art.
[0088] The following examples further illustrate the present invention, however, it should be understood that the description of the following examples is only used to understand the method of the present invention and its core concept. It should be pointed out that for those of ordinary skill in the art, without departing from the principles of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
[0089] Example 1 Preparation of Anti-L1CAM Protein Antibodies
[0090] 1. Experimental methods
[0091] 1) Immunogen processing: The immunogen is recombinant L1CAM protein. The protein purity and molecular weight were identified by SDS-PAGE and processed by ImmunoPlus technology to enhance immunogenicity.
[0092] 2) Animal immunization: BALB / c mice were selected and immunized by conventional methods. After three immunizations, the antiserum titer was tested by indirect ELISA method, and mice with high titer were selected for subsequent experiments. Western test was used to test the recognition of antiserum to recombinant antigen.
[0093] 3) Preparation of spleen cells: Kill the mouse by cervical stenosis, remove the spleen under sterile conditions, and place it in a sterilized 90-100 mesh stainless steel net. Use a syringe to inject 3 ml of serum-free culture medium into the spleen, repeatedly aspirate several times to obtain cells, and then make a cell suspension. Inject the cell suspension into a 50 ml centrifuge tube, add 10-20 ml of culture medium, gently blow several times, and let it stand at room temperature for 5 minutes. Centrifuge (800-1000 rpm), count, and set aside.
[0094] 4) Cell fusion: Mix mouse myeloma cells and mouse spleen cells in a ratio of 1:5, centrifuge and discard the supernatant, and absorb the excess supernatant with sterile filter paper. Add 1ml of 40% PEG solution dropwise to the cell mass within 60 seconds, while gently rotating the centrifuge tube. In the rotating centrifuge tube, add 1ml of serum-free culture medium dropwise within 60 seconds, and then slowly add 20ml of serum-free culture medium within 5 minutes, centrifuge (800 rpm, 8 minutes), remove the supernatant, suspend with 10ml of complete culture medium, and gently mix. Add the cell suspension to a 96-well plate, 50 microliters per well, and culture in a 37℃ CO2 incubator for 24 hours before replacing it with HAT selective culture medium.
[0095] 5) Post-fusion cell culture: 7-10 days after fusion, replace the medium with half of the HAT medium, and then replace the medium every 2-3 days. Hybrid cell colonies will appear after 2-3 weeks. When the colonies proliferate and grow to 1 / 3 of the well, use the indirect ELISA method to test the affinity of the monoclonal antibodies in the culture supernatant of mouse hybridoma cells.
[0096] 2. Experimental results
[0097] The sequence of the anti-L1CAM protein antibody 8D12 is shown in Table 1.
[0098] Table 1 Sequence of anti-L1CAM protein antibody 8D12
[0099]
[0100]
[0101] Example 2 Functional identification of anti-L1CAM protein antibodies
[0102] 1. Experimental methods
[0103] 1) Two neuronal exosomes (NDE1 and NDE2) were used as antigens and detected with monoclonal antibodies in the culture supernatant of mouse hybridoma cells, and the binding ability of antibodies and antigens was detected by western blot.
[0104] 2) The affinity of monoclonal antibodies in the culture supernatant of mouse hybridoma cells was tested by indirect ELISA method. The plate was coated with L1CAM recombinant protein as antigen, with the concentration of the coated antigen being 1 μg / ml, 100 μl / well; the coating buffer was PBS (PH=7.4); it was placed at 4℃ overnight; the next day, it was washed with PBS 3 times, 5 minutes each time; it was blocked with 1% BSA, 200 μl was added to each well; it was incubated in a 37℃ incubator for 2 hours; BSA was discarded, and cell culture supernatant containing monoclonal antibodies was added, 100 μl per well; blank culture supernatant was used as negative control; it was incubated in a 37℃ incubator for 2 hours; the primary antibody was discarded, the washing solution was washed 5 times, 2554 GoatAnti-Mouse IgG was added, and it was incubated in a 37℃ incubator for 1 hour; after adding substrate for color development, the absorbance was measured by an ELISA instrument.
[0105] 2. Experimental results
[0106] 1) Western blot was used to detect the binding ability of antibodies to NDE1 and NDE2. The results are as follows Figure 1 As shown, a strong positive band appeared at around 50KD, indicating that the antibody has a strong binding ability to neuronal exosomes.
[0107] 2) The results of the antibody affinity detection using the indirect ELISA method are shown in Table 2. The absorbance value of the antibody is >2, which is much larger than the negative control value of 0.063, indicating that the antibody has a good affinity for the recombinant protein antigen.
[0108] Table 2 Antibody recognition of recombinant proteins
[0109]
[0110] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. An antibody against L1CAM protein, characterized in that The antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises heavy chain complementary determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises light chain complementary determining regions LCDR1, LCDR2 and LCDR3; wherein: The amino acid sequences of the HCDR1, HCDR2 and HCDR3 are shown in SEQ ID NOs: 3, 4 and 5, respectively; the amino acid sequences of the LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NOs: 10, 11 and 12, respectively.
2. The antibody according to claim 1, characterized in that The antibody has any one of the amino acid sequences shown in (I)-(III): (I) the heavy chain variable region sequence shown in SEQ ID NO: 1 and the light chain variable region sequence shown in SEQ ID NO: 2; (II) an amino acid sequence that has at least 90% homology to the amino acid sequence shown in SEQ ID NO: 1-2 and has the same function; (III) An amino acid sequence obtained by modifying, replacing, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO: 1-2 and having the same function.
3. A biomaterial, characterized in that: It includes: 1) A polynucleotide encoding the antibody according to any one of claims 1 to 2; 2) a vector comprising the polynucleotide described in 1); 3) A host cell comprising the polynucleotide described in 1) or the vector described in 2).
4. The biomaterial according to claim 3, wherein the polynucleotide sequence encoding the heavy chain variable region of the antibody according to any one of claims 1 to 2 is shown as SEQ ID NO: 17; the polynucleotide sequence encoding the light chain variable region of the antibody according to any one of claims 1 to 2 is shown as SEQ ID NO:
18.
5. The biomaterial according to claim 4, characterized in that The vector includes linear polynucleotide, plasmid, and viral vector; the host cell includes prokaryotic cell and eukaryotic cell.
6. Any of the following methods, comprising: (1) A method for preparing the antibody according to any one of claims 1 to 2, characterized in that the method comprises the following steps: culturing the host cell according to any one of claims 3 or 5 to obtain a culture product, and isolating and purifying the antibody according to any one of claims 1 to 2 from the culture product; (2) A method for detecting L1CAM protein or neuronal exosomes in a sample for non-diagnostic purposes, characterized in that the method comprises the following steps: contacting the antibody according to any one of claims 1 to 2 with a sample to be tested, and detecting the formation of an immune complex between L1CAM protein or neuronal exosomes and the antibody; (3) A method for enriching CNS-derived exosomes, characterized in that the method comprises the step of contacting the antibody according to any one of claims 1 to 2 with a biological fluid of a subject.
7. An antibody derivative, characterized in that: The antibody derivative is a complex obtained by modifying the antibody according to any one of claims 1 to 2; the modification is modification by conjugation with a detectable marker or modification by conjugation with an imaging agent.
8. The antibody derivative according to claim 7, characterized in that The detectable markers include fluorescent pigments, avidin, radioisotopes, enzyme labels, dyes, and biotin.
9. A product, characterized in that The product comprises the antibody according to any one of claims 1-2, the biomaterial according to any one of claims 3-5, and the antibody derivative according to any one of claims 7-8.
10. An application, characterized in that: The application includes any of the following: 1) Use of the antibody according to any one of claims 1-2, the biological material according to any one of claims 3-5, or the antibody derivative according to any one of claims 7-8 in the preparation of a product for detecting, identifying or screening L1CAM protein; 2) Use of the antibody according to any one of claims 1-2, the biomaterial according to any one of claims 3-5, or the antibody derivative according to any one of claims 7-8 in the preparation of a product for detecting or capturing neuronal exosomes; 3) Use of the antibody according to any one of claims 1 to 2, the biomaterial according to any one of claims 3 to 5, or the antibody derivative according to any one of claims 7 to 8 in the preparation of a product for diagnosing neurodegenerative diseases.
Citation Information
Patent Citations
Antibody binding specifically to human and mouse L1cam protein, and use therefor
CN104936984A
Antigen polypeptide and monoclonal antibody applicable to enrichment of human L1CAM protein
CN107118271A
Anti-l1CAM antibodies and uses thereof
CN112689644A
Single-domain antibodies aiming at L1CAM as well as derivative protein and application of single-domain antibodies
CN113831411A
